How many employees does Rhythm Pharmaceuticals, Inc. have?

Rhythm Pharmaceuticals, Inc. reported 414 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 46.3% from a year earlier.

What is Rhythm Pharmaceuticals, Inc.'s revenue per employee?

Rhythm Pharmaceuticals, Inc. brought in $190M of revenue in fiscal Dec 2025, which is $458K per employee. That ranks 25 of 46 companies we track in Biotechnology, where the median is $574K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Rhythm Pharmaceuticals, Inc. employees and revenue per employee

RYTM · Biotechnology · $6.23B market cap

Rhythm Pharmaceuticals, Inc. had 414 employees at the end of fiscal Dec 2025, up 46.3% from a year earlier. Revenue for the year was $190M, up 45.8% from a year earlier, or $458K per employee. Headcount grew faster than revenue.

Employees

414

+46.3% YoY

Revenue

$190M

+45.8% YoY

Revenue / employee

$458K

Peer median $574K

Rank in industry

25 of 46

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2021

Hover a year for the numbers.

RYTM employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	414	$190M	$458K	+46.3%	+45.8%
Dec 2024	283	$130M	$460K	+25.2%	+68.1%
Dec 2023	226	$77.4M	$343K	+27.7%	+227.6%
Dec 2022	177	$23.6M	$134K	+26.4%	+649.5%
Dec 2021	140	$3.2M	$23K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Rhythm Pharmaceuticals, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
LGND Ligand Pharmaceuticals Incorporated	47	$268M	$5.70M	Leaner
KRYS Krystal Biotech, Inc.	295	$389M	$1.32M	Efficient growth
RYTM Rhythm Pharmaceuticals, Inc.	414	$190M	$458K	Hiring ahead
ADPT Adaptive Biotechnologies Corporation	624	$277M	$444K	Efficient growth
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth
IOVA Iovance Biotherapeutics, Inc.	975	$264M	$270K	Efficient growth
IBRX ImmunityBio, Inc.	691	$113M	$164K	Efficient growth
CYTK Cytokinetics, Incorporated	673	$88.0M	$131K	Efficient growth

Every Healthcare company

Questions about Rhythm Pharmaceuticals, Inc.

How many employees does Rhythm Pharmaceuticals, Inc. have?: Rhythm Pharmaceuticals, Inc. reported 414 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 46.3% from a year earlier.
What is Rhythm Pharmaceuticals, Inc.'s revenue per employee?: Rhythm Pharmaceuticals, Inc. brought in $190M of revenue in fiscal Dec 2025, which is $458K per employee. That ranks 25 of 46 companies we track in Biotechnology, where the median is $574K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare RYTM with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Rhythm Pharmaceuticals, Inc.'s annual reports (Form 10-K), latest filed February 26, 2026. This is data, not a recommendation to buy or sell RYTM.